-
Subject Areas on Research
-
18th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer. 30 October-2 November 2003, Bethesda, Maryland, USA.
-
A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model.
-
Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.
-
Adoptive immunotherapy for malignant glioma.
-
Adoptive immunotherapy with autologous T-cell infusions reduces opioid requirements in advanced cancer patients.
-
Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma.
-
Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer.
-
Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas.
-
Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites.
-
Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.
-
Attrition of memory CD8 T cells during sepsis requires LFA-1.
-
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial.
-
B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
-
B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.
-
BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
-
Blood microbiota diversity determines response of advanced colorectal cancer to chemotherapy combined with adoptive T cell immunotherapy.
-
CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains.
-
CAR T cells and checkpoint inhibition for the treatment of glioblastoma.
-
CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion.
-
CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies.
-
CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.
-
CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.
-
Characterization of tumor-specific cytotoxic effector cells with a novel CD3-/Thy-1+ phenotype.
-
Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3.
-
Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
-
Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.
-
Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy.
-
Circulating CD8+CD28- suppressor T cells tied to poorer prognosis among metastatic breast cancer patients receiving adoptive T-cell therapy: A cohort study.
-
Clinical immunotherapy for brain tumors.
-
Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).
-
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.
-
Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma.
-
Current status of adoptive immunotherapy of malignancies.
-
Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study.
-
Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.
-
Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy.
-
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.
-
Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease.
-
EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management.
-
Editorial: Infections of the immunocompromised host: a musing on the changing times.
-
Emerging antiviral therapeutics for human adenovirus infection: Recent developments and novel strategies.
-
Endothelial cell function and endothelial-related disorders following haematopoietic cell transplantation.
-
Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
-
Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs.
-
Ex vivo expansion, maturation, and activation of umbilical cord blood-derived T lymphocytes with IL-2, IL-12, anti-CD3, and IL-7. Potential for adoptive cellular immunotherapy post-umbilical cord blood transplantation.
-
Experimental trials of immunotherapy for malignant melanoma.
-
Facultative role of germinal centers and T cells in the somatic diversification of IgVH genes.
-
Flow cytometric detection of lymphocyte proliferation in eyes with immunogenic inflammation.
-
Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.
-
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
-
Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines.
-
Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care.
-
Generation of tumor-specific T lymphocytes for the treatment of posttransplant lymphoma.
-
Graft-versus-host reactions: anti-leukemia effects of donor T cells.
-
Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity.
-
Highlights from the 46 th annual meeting of the American Society of Hematology.
-
Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma.
-
Human gammadelta-T cells in adoptive immunotherapy of malignant and infectious diseases.
-
Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells.
-
Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40.
-
Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas.
-
Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors.
-
Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.
-
Immunoregulatory T cells in cancer immunotherapy.
-
Immunosurveillance by antiangiogenesis: tumor growth arrest by T cell-derived thrombospondin-1.
-
Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow.
-
Immunotherapy and monoclonal antibody therapies.
-
Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.
-
Immunotherapy for osteosarcoma: Where do we go from here?
-
Immunotherapy of malignant brain tumors.
-
Immunotherapy of surgical malignancies.
-
Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma.
-
Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8+ T cells.
-
Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: implications for cervical cancer immunotherapy.
-
Induction of protective CTL responses in newborn mice by a murine retrovirus.
-
Induction of specific tolerance by intrathymic injection of recipient muscle cells transfected with donor class I major histocompatibility complex.
-
Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4+ T-cell responses and tumor immunity.
-
In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
-
Is autologous stem cell transplantation still relevant for multiple myeloma?
-
Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond.
-
Lin-
CCR2+
hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade.
-
Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy.
-
MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation.
-
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy.
-
Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy.
-
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
-
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
-
Non-pharmacologic approaches to graft-versus-host prevention.
-
Oncolytic virus-derived type I interferon restricts CAR T cell therapy.
-
Ordinary Differential Equation Models for Adoptive Immunotherapy.
-
Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection.
-
Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma.
-
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
-
Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.
-
Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
-
Phase I trial of interleukin-2 plus doxorubicin.
-
Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.
-
Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.
-
Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models.
-
Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
-
Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts.
-
Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).
-
Prospects for cellular immunotherapy for metastatic melanoma.
-
Questionable relevance of gamma delta T lymphocytes in renal cell carcinoma.
-
RNA-Modified T Cells Mediate Effective Delivery of Immunomodulatory Cytokines to Brain Tumors.
-
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.
-
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.
-
Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells.
-
Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer.
-
Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection.
-
Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences.
-
Selective modification of antigen-specific T cells by RNA electroporation.
-
Sickle erythrocytes target cytotoxics to hypoxic tumor microvessels and potentiate a tumoricidal response.
-
Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors.
-
Single-cell imaging of T cell immunotherapy responses in vivo.
-
Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy.
-
Suppression of hepatic allograft rejection in the rat by mitomycin C-treated donor splenocytes: analysis of the immune status.
-
Synergy between tumor immunotherapy and antiangiogenic therapy.
-
Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study.
-
Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.
-
The Complex Integration of T-cell Metabolism and Immunotherapy.
-
The Landscape of Cell and Gene Therapies for Solid Tumors.
-
The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion.
-
The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.
-
The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity.
-
Thoracic metastasectomy for adoptive immunotherapy of melanoma: a single-institution experience.
-
Toward effective immunotherapy for the treatment of malignant brain tumors.
-
Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression.
-
Treatment of human melanoma hepatic metastases in nude mice with human cytotoxic T lymphocytes.
-
Tuberous sclerosis 1 promotes invariant NKT cell anergy and inhibits invariant NKT cell-mediated antitumor immunity.
-
Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.
-
Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL.
-
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma.
-
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.
-
Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials.
-
Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity.
-
WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy.
-
[Adjuvant therapy of surgically removed stage I melanoma].
-
gammadelta T cells: a new frontier for immunotherapy?
-
Keywords of People
-
-
-
Inman, Brant Allen,
Professor of Surgery,
Surgery, Urology
-
Palmer, Gregory M.,
Associate Professor of Radiation Oncology,
Radiation Oncology
-
Sampson, John Howard,
Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine,
Biomedical Engineering